Nivolumab, an anti-PD-1 antibody, can inhibit the interaction with PD-L1 on tumor cells by binding to PD-1 receptor on T cells, leading to restoration of the antitumor activity of T cells. The gene discussed is PDCD1; the disease is neoplasm.